Scientific Director, Translational Medicine
Bristol Myers Squibb, Summit, NJ, USA
Michael D. Amatangelo, PhD, is a Scientific Director of Translational Medicine at Bristol Myers Squibb, based in Summit, New Jersey. He currently serves as the late-stage translational development lead for the Iberdomide and Mezigdomide programs in Multiple Myeloma. Dr. Amatangelo earned his PhD in Molecular Cell Biology and Genetics from Drexel University College of Medicine in Philadelphia, Pennsylvania, and completed his postdoctoral fellowship at The Wistar Institute at the University of Pennsylvania.